Guggenheim Maintains Neutral Rating on Amgen, $378 Target
Guggenheim kept its Neutral rating on Amgen and a $378 price target. The target implies 9.5% downside from the Oct. 12 close of $417.57.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.